Lux Capital is a New York-based deep-tech venture firm with a long-standing reputation for backing breakthrough science and engineering. It invests from seed through later stages and is known for supporting highly technical companies across frontier domains. Compared with traditional healthcare VCs, Lux is much more comfortable with bold, science-first platform risk.

In neurotechnology, Lux has one of the strongest reputations in the field, with investments including CTRL-labs and Synchron. Its portfolio shows a long-term conviction around neural interfaces, neurostimulation, and the broader idea of the brain as a new computing frontier. Lux is especially notable for backing companies that combine deep technical novelty with potentially category-defining outcomes.

Lux invests globally and is among the defining institutional names in frontier neurotechnology. For neurotech founders, it is especially relevant to ambitious platform companies in BCI, neural sensing, interfaces, and high-conviction neuroengineering. It is one of the clearest top-tier fits for technically groundbreaking brain-computer and neural interface companies.